

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

Plandai Biotechnology, Inc.

4811 49th Street
San Diego, CA 92115

619-239-9034
No Current Website
plandai@protonmail.com
2833

First Amended Quarterly Report **For the Period Ending: March 31, 2022** (the "Reporting Period")

As of March 31, 2022, the number of shares outstanding of our Common Stock was:

6,806,411,205

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

6,806,411,205

As of September 30, 2021, the number of shares outstanding of our Common Stock was:

5,616,411,205

As of June 30, 2021, the number of shares outstanding of our Common Stock was:

4,962,623,280

As of June 30, 2020, the number of shares outstanding of our Common Stock was:

943,928,137

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Jerry's, Inc. from 1942 to 2004
Diamond Ranch Foods, Inc. from 2004 to 2012
Plandai Biotechnology, Inc. from 2012 to present

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada; the issuer is active and in good standing

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

4811 49th Street
San Diego, CA 92115

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: No:

¹ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

2) Security Information

Trading symbol: PLPL
Exact title and class of securities outstanding: Common
CUSIP: 72703D100
Par or stated value: \$0.0001

Total shares authorized: 11,000,000,000 as of date: March 31, 2022
Total shares outstanding: 6,806,411,205 as of date: March 31, 2022
Number of shares in the Public Float²: 6,262,077,154 as of date: March 31, 2022
Total number of shareholders of record: 119 as of date: March 31, 2022

All additional class(es) of publicly traded securities (if any):

Trading symbol: _____
Exact title and class of securities outstanding: _____
CUSIP: _____
Par or stated value: _____
Total shares authorized: _____ as of date: _____
Total shares outstanding: _____ as of date: _____

Transfer Agent

Name: Signature Stock Transfer
Phone: 972-612-4120
Email: jason@signaturestocktransfer.com
Address: 14673 Midway Road Ste. 220, Addison TX 75001

Is the Transfer Agent registered under the Exchange Act?³ Yes: No:

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
<u>Opening Balance</u>									
Date <u>June 30, 2020</u> Common: <u>943,928,137</u> Preferred: <u>100,000</u>									
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>7-10-20</u>	<u>Issuance</u>	<u>47,100,000</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>8-13-20</u>	<u>Issuance</u>	<u>48,431,417</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>8-25-20</u>	<u>Issuance</u>	<u>51,168,042</u>	<u>Common</u>	<u>0.00016</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>9-4-20</u>	<u>Issuance</u>	<u>22,763,292</u>	<u>Common</u>	<u>0.00015</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>9-11-20</u>	<u>Issuance</u>	<u>55,554,167</u>	<u>Common</u>	<u>0.00016</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>9-18-20</u>	<u>Issuance</u>	<u>58,078,500</u>	<u>Common</u>	<u>0.00017</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>9-18-20</u>	<u>Issuance</u>	<u>55,555,556</u>	<u>Common</u>	<u>0.00017</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>9-24-20</u>	<u>Issuance</u>	<u>30,842,611</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>11-18-20</u>	<u>Issuance</u>	<u>65,500,000</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>

<u>11-19-20</u>	<u>Issuance</u>	<u>68,882,222</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>11-24-20</u>	<u>Issuance</u>	<u>72,255,556</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>11-30-20</u>	<u>Issuance</u>	<u>79,446,667</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>11-30-20</u>	<u>Issuance</u>	<u>79,811,111</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-2-20</u>	<u>Issuance</u>	<u>83,805,556</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-7-20</u>	<u>Issuance</u>	<u>83,333,333</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-9-20</u>	<u>Issuance</u>	<u>87,988,889</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-11-20</u>	<u>Issuance</u>	<u>96,538,889</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-17-20</u>	<u>Issuance</u>	<u>101,355,556</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-21-20</u>	<u>Issuance</u>	<u>106,416,667</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-28-20</u>	<u>Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>0.00017</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-28-20</u>	<u>Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-28-20</u>	<u>Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-28-20</u>	<u>Issuance</u>	<u>25,000,000</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-28-20</u>	<u>Issuance</u>	<u>11,685,389</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>

						<u>Aryeh Goldstein</u>			
<u>12-31-20</u>	<u>Issuance</u>	<u>116,579,611</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>1-8-21</u>	<u>Issuance</u>	<u>69,466,944</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>1-12-21</u>	<u>Issuance</u>	<u>122,264,389</u>	<u>Common</u>	<u>0.00016</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>1-15-21</u>	<u>Issuance</u>	<u>89,194,444</u>	<u>Common</u>	<u>0.00014</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>1-21-21</u>	<u>Issuance</u>	<u>52,450,444</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>1-22-21</u>	<u>Issuance</u>	<u>239,053,333</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>1-28-21</u>	<u>Issuance</u>	<u>240,208,889</u>	<u>Common</u>	<u>0.00017</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>2-9-21</u>	<u>Issuance</u>	<u>239,285,167</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>2-19-21</u>	<u>Issuance</u>	<u>111,606,000</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>3-5-21</u>	<u>Issuance</u>	<u>60,281,445</u>	<u>Common</u>	<u>0.00015</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>3-22-21</u>	<u>Issuance</u>	<u>246,816,667</u>	<u>Common</u>	<u>0.00017</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>4-23-21</u>	<u>Issuance</u>	<u>354,252,111</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>5-4-21</u>	<u>Issuance</u>	<u>223,808,667</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>5-12-21</u>	<u>Issuance</u>	<u>222,808,667</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>

<u>5-26-21</u>	<u>Issuance</u>	<u>224,104,945</u>	<u>Common</u>	<u>0.00018</u>	<u>Yes</u>	<u>Adar Bays, LLC</u> <u>Aryeh Goldstein</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>7-7-21</u>	<u>Issuance</u>	<u>188,787,925</u>	<u>Common</u>	<u>0.00035</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>8-2-21</u>	<u>Issuance</u>	<u>200,000,000</u>	<u>Common</u>	<u>0.0003</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>8-30-21</u>	<u>Issuance</u>	<u>265,000,000</u>	<u>Common</u>	<u>0.00015</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>10-04-21</u>	<u>Issuance</u>	<u>280,000,000</u>	<u>Common</u>	<u>0.00004</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>10-18-21</u>	<u>Issuance</u>	<u>290,000,000</u>	<u>Common</u>	<u>0.00006</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>10-28-21</u>	<u>Issuance</u>	<u>300,000,000</u>	<u>Common</u>	<u>0.00004</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
<u>12-10-21</u>	<u>Issuance</u>	<u>320,000,000</u>	<u>Common</u>	<u>0.00004</u>	<u>Yes</u>	<u>EMA Financial, LLC</u> <u>Felicia Preston</u>	<u>Debt</u> <u>Conversion</u>	<u>Unrestricted</u>	<u>4(a)(1)</u>
Shares Outstanding on Date of This Report:									
Date: <u>March 31, 2022</u> Ending Balance:									
Common: <u>6,806,411,205</u>									
Preferred: <u>100,000</u>									

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended June 30, 2021, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2019 through June 30, 2021 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
<u>9-21-16</u>	<u>68,397.30</u>	<u>57,500</u>	<u>68,397.30</u>	<u>9/21/17</u>	<u>50% of lowest traded price during 25 consecutive trading days prior to the conversion date.</u>	<u>Pinnacle Consulting Services, Inc. (Robert Hymers)</u>	<u>Loan</u>
<u>11-3-20</u>	<u>85,557.32</u>	<u>75,000</u>	<u>10,557.32</u>	<u>11-3-22</u>	<u>40% of lowest traded price during 20 consecutive trading days prior to the conversion date with a holdings limit of 4.99% of total outstanding shares.</u>	<u>Pinnacle Tax Services, Inc. (Robert Hymers)</u>	<u>Consulting</u>
<u>10-31-20</u>	<u>7,940.51</u>	<u>6,675</u>	<u>1,265.51</u>	<u>10-31-21</u>	<u>Fair market value at time of conversion.</u>	<u>Adar Bays, LLC (Ari Goldstein)</u>	<u>Securities Purchase Agreement</u>
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Nicholas Coleck
Title: Accountant
Relationship to Issuer: Consultant

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

- C. Balance Sheet;
- D. Statement of Income;
- E. Statement of Cash Flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

No operations.

- B. Please list any subsidiaries, parents, or affiliated companies.

No current subsidiaries, parents or affiliated companies.

- C. Describe the issuers' principal products or services.

The Company is a publicly quoted shell company seeking to create value for its shareholders by merging with another entity with experienced management and opportunities for growth. No potential merger candidate has been identified at this time.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company has no current leases for any assets, properties or facilities.

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
<u>Tad Mailander</u>	<u>Director, CEO, CFO</u>	<u>4811 49th Street San Diego, CA 92115</u>	<u>100,000</u>	Series A Preferred	<u>100%</u>	<u>Voting preference equal to the number is shares eligible to vote plus one.</u>
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

No pending legal proceedings.

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Priscilla Bazan
Firm: Law Office of Priscilla Bazan
Address 1: 744 South Street #869
Address 2: Philadelphia, PA 19147
Phone: 267-939-7000
Email: corcounsel@gmail.com

Accountant or Auditor

Name: Nicholas Coleck
Firm: Pinnacle Tax Services
Address 1: 520 South Grand Avenue, #320
Address 2: Los Angeles, CA 90071
Phone: _____
Email: nicholas.coleck@pinnacletaxandaccounting.com

Investor Relations

Name: _____
Firm: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

Name: _____
Firm: _____

Nature of Services: _____
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Tad Mailander, Chief Executive Officer certify that:

1. I have reviewed this quarterly report for the quarter ended March 31, 2022 of Plandai Biotechnology, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 19, 2022 [Date]

/s/ Tad Mailander, Acting Chief Executive Officer [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, Tad Mailander certify that:

1. I have reviewed this quarterly report for the quarter ended March 31, 2022 of Plandai Biotechnology, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 19, 2022 [Date]

/s/ Tad Mailander, Acting Chief Financial Officer [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

PLANDAI BIOTECHNOLOGY, INC.
Consolidated Balance Sheets
(Unaudited)

	March 31	June 30
	2022	2021
	<hr/>	<hr/>
ASSETS		
Current Assets:		
Related Party Receivable	\$ -	\$ 573,720
Total Current Assets	<hr/> -	<hr/> 573,720
Other Assets:		
Fixed Assets, net	-	6,687,083
TOTAL ASSETS	<hr/> <hr/> \$ -	<hr/> <hr/> \$ 7,260,803
LIABILITIES & STOCKHOLDERS' EQUITY		
Current Liabilities:		
Accounts Payable and Accrued Liabilities	\$ 188,403	\$ 1,363,347
Accrued Interest	80,220	998,560
Convertible Notes Payable, net	81,675	171,272
Short-Term Portion of Notes Payable	-	18,613,649
Derivative Liability	10,997	1,440,106
Related Party Payables	-	1,603
Total Current Liabilities	<hr/> 361,295	<hr/> 22,588,537
Other Liabilities:		
Loans from Related Party	-	2,629,813
Deferred Lease Obligations	-	20,903
Total Liabilities	<hr/> 361,295	<hr/> 25,239,253
Stockholders' Equity (Deficit):		
Common Stock, Par Value \$0.0001, 11,000,000,000 shares authorized; of which 6,806,411,205 and 4,962,623,280 shares issued and outstanding as of December 31, 2021 and June 30, 2021, respectively	\$ 680,640	\$ 496,262
Preferred Stock	100	100
Additional Paid-In capital	36,937,634	36,902,787
Accumulated Deficit	(37,979,669)	(51,403,962)
Cumulative Foreign Currency Translation Adjustment	-	(1,923,074)
Total Stockholder's Equity (Deficit)	<hr/> (361,295)	<hr/> (15,927,887)
Non-Controlling Interest	-	(2,050,563)
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT	<hr/> <hr/> \$ -	<hr/> <hr/> \$ 7,260,803

The accompanying notes are an integral part of these unaudited consolidated financial statements

PLANDAI BIOTECHNOLOGY, INC.
Consolidated Statements of Operations
(Unaudited)

	For The Three Months Ended March 31,		For The Nine Months Ended March 31,	
	2022	2021	2022	2021
Revenues	\$ -	\$ -	\$ -	\$ -
Cost of Goods	-	-	-	-
Gross Profit	-	-	-	-
Expenses:				
Consulting	-	-	-	75,000
Total Operating Expenses	-	-	-	75,000
Operating Income (Loss)	-	-	-	(75,000)
Other Income (Expense)				
Interest Expense	(2,047)	-	(256,117)	-
Income from Cancellation of Debt	-	-	7,920,809	-
Write-Off of Fixed Assets	-	-	(6,687,083)	-
Change in Derivative Liability	(2,848)	-	1,429,109	-
Total Other Income (Expense)	(4,895)	-	2,406,718	-
Net Income (Loss)	\$ (4,895)	\$ -	\$ 2,406,718	\$ (75,000)
Income (Loss) Allocated to Non-controlling Interest	\$ -	\$ -	\$ -	\$ -
Net Income (Loss), Adjusted	\$ (4,895)	\$ -	\$ 2,406,718	\$ (75,000)
Other Comprehensive Income (Loss):				
Foreign Currency Translation Adjustment	\$ -	\$ -	\$ -	\$ -
Comprehensive Income (Loss)	\$ (4,895)	\$ -	\$ 2,406,718	\$ (75,000)
Basic and diluted loss per common share	\$ (0.000)	\$ -	\$ 0.000	\$ (0.000)
Weighted average common shares outstanding	6,806,411,205	2,167,947,493	6,186,694,254	1,513,086,190

The accompanying notes are an integral part of these unaudited consolidated financial statements

PLANDAI BIOTECHNOLOGY, INC.
Consolidated Statements of Stockholders' Equity
For The Nine Months Ended March 31, 2022

	Class A Preferred Stock		Common Stock		Additional	Accumulated	Cumulative	Total
	Shares	Amount	Shares	Amount	Paid In Capital Amount	Deficit Amount	Foreign Currency Translation Adjustment Amount	Amount
Balance, June 30, 2020	100	\$ 100	943,928,137	\$ 94,392	\$ 36,157,048	\$ (51,255,992)	\$ (1,923,074)	\$ (16,927,526)
Issuance of Stock for Debt Conversions	-	-	4,018,695,143	401,870	745,739	-	-	1,147,609
Prior period adjustment to deficit	-	-	-	-	-	(79,333)	-	(79,333)
Net Loss	-	-	-	-	-	(68,636)	-	(68,636)
Balance, June 30, 2021	100	\$ 100	4,962,623,280	\$ 496,262	\$ 36,902,787	\$ (51,403,962)	\$ (1,923,074)	\$ (15,927,887)
Balance, June 30, 2021	100	\$ 100	4,962,623,280	\$ 496,262	\$ 36,902,787	\$ (51,403,962)	\$ (1,923,074)	\$ (15,927,887)
Issuance of Stock for Debt Conversions	-	-	653,787,925	65,379	165,826	-	-	231,205
Prior period adjustment to deficit	-	-	-	-	-	(230,403)	-	(230,403)
Net Income	-	-	-	-	-	(190,431)	-	(190,431)
Balance, September 30, 2021	100	\$ 100	5,616,411,205	\$ 561,640	\$ 37,068,613	\$ (51,824,795)	\$ (1,923,074)	\$ (16,117,516)
Balance, September 30, 2021	100	\$ 100	5,616,411,205	\$ 561,640	\$ 37,068,613	\$ (51,824,795)	\$ (1,923,074)	\$ (16,117,516)
Issuance of Stock for Debt Conversions	-	-	1,190,000,000	119,000	(65,600)	-	-	53,400
Prior period adjustment to paid-in capital	-	-	-	-	(65,379)	-	-	(65,379)
Prior period adjustment to deficit	-	-	-	-	-	11,845,012	-	11,845,012
Net Income	-	-	-	-	-	2,602,044	-	2,602,044
Balance, December 31, 2021	100	\$ 100	6,806,411,205	\$ 680,640	\$ 36,937,634	\$ (37,377,740)	\$ (1,923,074)	\$ (1,682,439)
Balance, December 31, 2021	100	\$ 100	6,806,411,205	\$ 680,640	\$ 36,937,634	\$ (37,377,740)	\$ (1,923,074)	\$ (1,682,439)
Prior period adjustment to Accumulated Deficit	-	-	-	-	-	(726,769)	1,923,074	1,196,305
Effects of Change in Derivative Liability	-	-	-	-	-	129,735	-	129,735
Net Income	-	-	-	-	-	(4,895)	-	(4,895)
Balance, March 31, 2022	100	\$ 100	6,806,411,205	\$ 680,640	\$ 36,937,634	\$ (37,979,669)	\$ -	\$ (361,295)

The accompanying notes are an integral part of these unaudited consolidated financial statements

PLANDAI BIOTECHNOLOGY, INC.
Consolidated Statements of Cash Flows
(Unaudited)

	For The Nine Months Ended	
	March 31,	
	<u>2022</u>	<u>2021</u>
Cash Flow From Operating Activities		
Net Income (Loss)	\$ 2,406,718	\$ (75,000)
Adjustments to reconcile net loss to net cash used in operating activities:		
Prior Period Adjustment to Deficit	12,912,614	-
Prior Period Adjustment to Paid-In Capital	(65,379)	-
Prior Period Write-Off of Debt	(10,692,840)	-
Effect of Change in Derivative Liability	(1,429,109)	-
Write-Off of Fixed Assets	6,687,083	-
Income from Cancellation of Debt	(7,920,809)	-
Issuance of Stock for Debt Conversions	284,604	-
Accrued Expenses	-	75,000
Changes in working capital		
Decrease in Accounts Payable and Accrued Liabilities	(1,174,944)	-
Decrease in Accrued Interest	(918,340)	-
Decrease in Convertible Notes Payable, net	(89,597)	-
Net Cash Used in Operating Activities	<u>-</u>	<u>-</u>
Cash Flow From Investing Activities		
Net Cash From Investing Activities	<u>-</u>	<u>-</u>
Cash Flow From Financing Activities		
Proceeds from Issuing Convertible Debt	-	-
Net Cash From Financing Activities	<u>-</u>	<u>-</u>
Effect of Exchange Rates on Cash Flows	<u>-</u>	<u>-</u>
Net Change in Cash	<u>-</u>	<u>-</u>
Cash at Beginning of Period	<u>-</u>	<u>-</u>
Cash at End of Period	<u>\$ -</u>	<u>\$ -</u>
Net cash paid for:		
Interest	<u>\$ -</u>	<u>\$ -</u>
Income Taxes	<u>\$ -</u>	<u>\$ -</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements

Plandai Biotechnology, Inc
Notes to the Financial Statements
For the quarter ended March 31, 2022

NOTE 1 - ORGANIZATION AND OPERATIONS

Current Operations

Plandai Biotechnology, Inc. (“ PLPL ” or the “ Company “), a Nevada corporation, is a publicly quoted shell company. The Company's current operations are conducted at offices provided without charge in San Diego, California. PLPL does not have any ownership interest in the offices and there is no lease for the offices. The Company expects to utilize these offices indefinitely, pending the Company's possible merger with another entity. PLPL owns intellectual properties related to its prior research, development and production of botanical extracts including, but not limited to: trademarks, trade secrets, and product formulations for green tea and citrus products from discontinued operations. The Company's intellectual properties were the result of research and development endeavors with North-West University in Potchefstroom, South Africa, and the Company's former Senteeko Tea Estate located in Mpumalanga, South Africa.

Business Plan

PLPL is seeking to create value for its shareholders by merging with another entity with experienced management and opportunities for growth. No potential merger candidate has been identified at this time

Corporate Management

The Company is managed by Tad Mailander, who serves as PLPL’s acting CEO and President. Prior to Mr. Mailander’s appointment, Roger Duffield was the sole officer and director of the Company until his resignation on November 10, 2020.

Corporate History

The Company was incorporated in the State of Nevada on February 24, 2004. PLPL has since remained incorporated in Nevada. The Company currently operates as a shell company.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim unaudited financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited financial statements include all adjustments (consisting of normal recurring adjustments) which are, in the opinion of management, necessary in order to make the condensed financial statements not misleading. Notes to the financial statements which would substantially duplicate the disclosures contained in the annual financial statements for the most recent fiscal period, as reported in the Annual Report, have been omitted.

Recently Adopted Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Income Taxes

The Company accounts for income taxes using the asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax law. For deferred tax assets, management evaluates the probability of realizing the future benefits of such assets. The Company establishes valuation allowances for its deferred tax assets when evidence suggests it is unlikely that the assets will be fully realized. The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not to be sustained based solely on its technical merits as of the reporting date and then only in an amount more likely than not to be sustained upon review by the tax authorities. Income tax positions that previously failed to meet the more likely than not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more likely than not threshold are derecognized in the first subsequent financial reporting period in which that threshold is no longer met. The Company classifies potential accrued interest and penalties related to unrecognized tax benefits within the accompanying consolidated statements of operations and comprehensive income (loss) as income tax expense.

Stock-based Compensation

The Company has share-based compensation plans under which employees, consultants, suppliers and directors may be granted restricted stock, as well as options and warrants to purchase shares of Company common stock at the fair market value at the time of grant. Stock-based compensation cost to employees is measured by the Company at the grant date, based on the fair value of the award, over the requisite service period under ASC 718. For options issued to employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit. Grants of stock to non-employees and other parties are accounted for in accordance with the ASC 505.

Basic Income (Loss) Per Share

Under the provisions of ASC 260, "Earnings per Share," basic loss per common share is computed by dividing net loss available to common shareholders by the weighted average number of shares of common stock outstanding for the periods presented. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the income

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the financial statements, the Company has incurred recurring net losses since its inception and has raised limited capital. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The financial statements do not include any adjustment relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company is taking certain steps to provide the necessary capital to continue its operations. These steps include but are not limited to: 1) focus on our new business model and 2) raising equity or debt financing.

NOTE 4 – CONVERTIBLE NOTES

On September 21, 2016, the Company entered into a convertible note payable with an outside party for \$57,500 that matured on September 21, 2017. The note is convertible to common shares at 50% of lowest traded price during 25 consecutive trading days prior to the conversion date. The Company is currently in default on this note.

On November 3, 2020, the Company entered into a convertible note payable with Pinnacle Tax Services Inc. for \$75,000. The note is subject to 10% interest annually and is convertible to common shares at 40% of lowest traded price during 20 consecutive trading days prior to the conversion date with a holdings limit of 4.99% of total outstanding shares.

On January 27, 2022, EMA Financial, LLC sold its remaining \$68,397.30 of accrued interest of its convertible debt to Pinnacle Consulting Services, Inc., in exchange for \$60,000 per a Purchase and Assignment Agreement dated January 26, 2022.

NOTE 5 – PREFERRED STOCK

The Corporation is authorized to issue one class of Shares designated as “Preferred Stock” in the amount of One Hundred Thousand (100,000) Shares with a par value of \$0.001.

NOTE 6 – DERIVATIVE FINANCIAL INSTRUMENTS

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses the Black-Scholes Option Pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of December 31, 2021, the Company’s only derivative financial instruments were embedded conversion features associated with long-term convertible notes payable which contain certain provisions that allow for a variable number of shares on conversion. On December 3, 2021, Plandai Biotechnology, Inc. executed a settlement agreement and release of claims with legacy creditor Berkshire Capital Management Co., Inc.

Pursuant to the terms of the settlement, in exchange for a mutual release of all claims, Berkshire agreed to release Plandai from any and all obligations to pay principal and accrued interest under unsecured promissory notes totaling principal of \$6,900,000.

NOTE 7 – SETTLEMENTS AND RELEASES

On December 3, 2021, Plandai Biotechnology, Inc. executed a settlement agreement and release of claims with legacy creditor Berkshire Capital Management Co., Inc.

Pursuant to the terms of the settlement, in exchange for a mutual release of all claims, Berkshire agreed to release Plandai from any and all obligations to pay principal and accrued interest under unsecured promissory notes totaling principal of \$6,900,000.

NOTE 8 – EQUITY TRANSACTIONS

On October 4, October 18, and October 28, 2021, EMA Financial, LLC, holder of a convertible note, executed its fourth, fifth, and sixth debt conversions, resulting in the issuance of 280,000,000, 290,000,000, and 300,000,000 shares of common

stock, respectively, to EMA Financial, LLC. These debt conversions reduced the principal and interest balances of their convertible note payable to \$0 and \$68,397.30, respectively, as of March 31, 2022.

NOTE 9 – DISCONTINUED OPERATIONS

As previously stated, the Company no longer acts on its initial operations, but instead is currently in the state of being a shell company. The Company holds no current assets other than Related Party Receivables, and holds no other assets other than Fixed Assets, as of March 31, 2022. There was no revenue produced within the period, as entity was acting as a shell for the period. Expenses incurred in period were related to prorated accrued interest on convertible debt.

NOTE 10 – RELATED PARTY TRANSACTIONS

Management has evaluated subsequent events pursuant to the requirements of ASC Topic 850 and has determined that no material subsequent events exist through the date of this filing apart from the following:

None noted.

NOTE 11 – SUBSEQUENT EVENTS

On May 10, 2022, Pinnacle Consulting Services, Inc. converted \$30,000 of its Convertible Note into 200 million (200,000,000) shares of common stock, at a conversion price of \$0.00015 per shares. There remains a balance of \$38,397.30 of principal and original accrued interest balance remaining on the note following the conversion.